Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models.

Journal Article

Pancreatic cancer is an aggressive malignancy with morbidity rates almost equal to mortality rates because of the current lack of effective treatment options. Here, we describe a targeted approach to treating pancreatic cancer with effective therapeutic efficacy and safety in noninvasive imaging models. We developed a versatile expression vector "VISA" (VP16-GAL4-WPRE integrated systemic amplifier) and a CCKAR (cholecystokinin type A receptor) gene-based, pancreatic-cancer-specific promoter VISA (CCKAR-VISA) composite to target transgene expression in pancreatic tumors in vivo. Targeted expression of BikDD, a potent proapoptotic gene driven by CCKAR-VISA, exhibited significant antitumor effects on pancreatic cancer and prolonged survival in multiple xenograft and syngeneic orthotopic mouse models of pancreatic tumors with virtually no toxicity.

Full Text

Duke Authors

Cited Authors

  • Xie, X; Xia, W; Li, Z; Kuo, H-P; Liu, Y; Li, Z; Ding, Q; Zhang, S; Spohn, B; Yang, Y; Wei, Y; Lang, J-Y; Evans, DB; Chiao, PJ; Abbruzzese, JL; Hung, M-C

Published Date

  • July 2007

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 52 - 65

PubMed ID

  • 17613436

Electronic International Standard Serial Number (EISSN)

  • 1878-3686

International Standard Serial Number (ISSN)

  • 1535-6108

Digital Object Identifier (DOI)

  • 10.1016/j.ccr.2007.05.009

Language

  • eng